Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.33 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.33 |
| ▸ | TPH1 | P17752 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL733249 | 1.00 | F10 (0.36) | F10SCN9APTGDR2PTGDRTBXA2R | |
| SCHEMBL734195 | 0.93 | F10 (0.35) | F10SCN9APTGDR2PTGDRTBXA2R | |
| SCHEMBL731688 | 0.93 | SCN9A (0.37) | SCN9APTGDR2PTGDRTBXA2RCYP2C9 | |
| SCHEMBL734196 | 0.93 | F10 (0.35) | F10SCN9APTGDR2PTGDRTBXA2R | |
| SCHEMBL731687 | 0.93 | SCN9A (0.37) | SCN9APTGDR2PTGDRTBXA2RCYP2C9 | |
| SCHEMBL732785 | 0.92 | SCN9A (0.35) | F10SCN9APTGDR2NPC1TPH1 | |
| SCHEMBL732786 | 0.92 | SCN9A (0.35) | F10SCN9APTGDR2NPC1TPH1 | |
| SCHEMBL733715 | 0.91 | F10 (0.35) | F10SCN9APTGDR2PTGDRTBXA2R | |
| SCHEMBL733714 | 0.91 | F10 (0.35) | F10SCN9APTGDR2PTGDRTBXA2R | |
| SCHEMBL733188 | 0.90 | PTGDR2 (0.35) | SCN9APTGDR2PTGDRTBXA2RCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420675-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2013-04-16 | — | — | US | claimed |
| EP-2307383-B1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2012-05-16 | — | — | EP | claimed |
| US-20120101131-A1 | Aminotetrahydroindazoloacetic Acids | CHEN LI (CN) | 2012-04-26 | — | — | US | claimed |
| US-20100016369-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | claimed |
| US-8420675-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2013-04-16 | — | — | US | disclosed |
| EP-2307383-B1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2012-05-16 | — | — | EP | disclosed |
| US-20120101131-A1 | Aminotetrahydroindazoloacetic Acids | CHEN LI (CN) | 2012-04-26 | — | — | US | disclosed |
| US-8138208-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100016369-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101131-A1 | Aminotetrahydroindazoloacetic Acids | HRH2, HRH1, HRH4 | F10 736/4885SCN9A 2017/4885PTGDR2 16/4885 |
| US-20100016369-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HRH2, HRH1, HRH4 | F10 736/4885SCN9A 2017/4885PTGDR2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.